Cara's No-Brainer Opioid Solution

Cara Therapeutics Inc. believes its CR845 kappa opioid agonist will fare better than others because the peptide is too large to cross the blood-brain barrier, meaning it should avoid the side effects and narrow therapeutic windows associated with CNS receptor activation.

The company presented data from a Phase II trial to treat acute post-operative pain earlier this month, showing CR845 met the co-primary endpoint of pain reduction 4-8 hours after dosing...